In December 2014, they published a paper in Nature Medicine, showing that the triple agonists weight loss effects in mice exceeded those of the dual agonists
[DOI] [PubMed] [Google Scholar] 156.Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, et al
Common Humana Denial Reasons "Plan exclusion" Weight loss is not a covered indication (most common) "Missing diagnosis code" Pharmacy didn't submit ICD-10 code (resubmit, don't appeal) "Prior auth not obtained" Medicaid plans require PA before filling "Step therapy required" Must try other meds first (Saxenda, Contrave) When an Appeal Makes Sense Medicaid PA denial you meet criteria but were denied anyway OSA coverage dispute Medicare denied despite valid sleep apnea diagnosis Wrong diagnosis code your doctor listed the wrong indication Renewal denial you showed 5% weight loss but were still denied If your situation fits one of these, appeals can work
Docket 2026-08552
Both, SGLT2 inhibitors and GLP1 receptor agonists, had similar effect on MACE reduction, but SGLT2 inhibitors have far more benefits in patients with heart failure